WO2022244447A1 - 破骨前駆細胞の破骨細胞への分化抑制用組成物及び骨代謝改善用組成物 - Google Patents
破骨前駆細胞の破骨細胞への分化抑制用組成物及び骨代謝改善用組成物 Download PDFInfo
- Publication number
- WO2022244447A1 WO2022244447A1 PCT/JP2022/013051 JP2022013051W WO2022244447A1 WO 2022244447 A1 WO2022244447 A1 WO 2022244447A1 JP 2022013051 W JP2022013051 W JP 2022013051W WO 2022244447 A1 WO2022244447 A1 WO 2022244447A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- cells
- lactic acid
- processed product
- osteoclasts
- Prior art date
Links
- 210000002997 osteoclast Anatomy 0.000 title claims abstract description 97
- 210000004027 cell Anatomy 0.000 title claims abstract description 95
- 239000000203 mixture Substances 0.000 title claims abstract description 94
- 239000002243 precursor Substances 0.000 title claims abstract description 47
- 230000004069 differentiation Effects 0.000 title claims abstract description 46
- 230000004097 bone metabolism Effects 0.000 title claims abstract description 31
- 230000005764 inhibitory process Effects 0.000 title description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 110
- 239000000047 product Substances 0.000 claims abstract description 77
- 210000002865 immune cell Anatomy 0.000 claims abstract description 55
- 239000004310 lactic acid Substances 0.000 claims abstract description 55
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 55
- 241000894006 Bacteria Species 0.000 claims abstract description 53
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 50
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 46
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 46
- 239000012228 culture supernatant Substances 0.000 claims abstract description 45
- 238000012258 culturing Methods 0.000 claims abstract description 21
- 230000037182 bone density Effects 0.000 claims abstract description 19
- 208000001132 Osteoporosis Diseases 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 6
- 241000186660 Lactobacillus Species 0.000 claims description 5
- 229940039696 lactobacillus Drugs 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 230000006872 improvement Effects 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 16
- 238000004113 cell culture Methods 0.000 abstract description 9
- 230000009467 reduction Effects 0.000 abstract description 7
- 238000000034 method Methods 0.000 description 51
- 230000000694 effects Effects 0.000 description 33
- 235000013305 food Nutrition 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 239000002609 medium Substances 0.000 description 16
- 208000006386 Bone Resorption Diseases 0.000 description 14
- 210000000988 bone and bone Anatomy 0.000 description 14
- 230000024279 bone resorption Effects 0.000 description 14
- 238000011156 evaluation Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 239000000654 additive Substances 0.000 description 8
- 230000001629 suppression Effects 0.000 description 8
- 210000000459 calcaneus Anatomy 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- -1 infusions Substances 0.000 description 4
- 235000012149 noodles Nutrition 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 230000011164 ossification Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- 208000010392 Bone Fractures Diseases 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010024305 Leukaemia monocytic Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102000010498 Receptor Activator of Nuclear Factor-kappa B Human genes 0.000 description 2
- 108010038036 Receptor Activator of Nuclear Factor-kappa B Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 2
- 229940032049 enterococcus faecalis Drugs 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000000474 heel Anatomy 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 201000006894 monocytic leukemia Diseases 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 235000021395 porridge Nutrition 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000000273 veterinary drug Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000609240 Ambelania acida Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241001468229 Bifidobacterium thermophilum Species 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 241000186679 Lactobacillus buchneri Species 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 241000194038 Lactococcus plantarum Species 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000007591 Tartrate-Resistant Acid Phosphatase Human genes 0.000 description 1
- 108010032050 Tartrate-Resistant Acid Phosphatase Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000010905 bagasse Substances 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 235000014048 cultured milk product Nutrition 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000000010 osteolytic effect Effects 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 235000016046 other dairy product Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940056211 paraffin Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- 239000008256 whipped cream Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a composition for suppressing the differentiation of osteoclast precursor cells into osteoclasts and a composition for improving bone metabolism.
- Osteoporosis is a disease that makes bones fragile and prone to fracture. Bone contains two types of cells: osteoblasts responsible for bone formation and osteoclasts responsible for bone resorption. Sometimes. If the state in which the amount of bone resorption relatively exceeds the amount of bone formation continues, bone mass decreases and osteoporosis develops. There are about 10 million or more patients in Japan, and the number of patients with osteoporosis tends to increase as the population ages. As one method for improving osteoporosis, it is known to suppress the differentiation of osteoclast precursor cells (osteoclast precursor cells) into osteoclasts (Patent Document 1). On the other hand, lactic acid bacteria are known to have an immunostimulatory effect (Patent Document 2).
- JP 2010-235534 A Japanese Patent Application Laid-Open No. 2010-6801
- the culture supernatant of immune cells obtained by culturing immune cells in the presence of lactic acid bacteria or a processed product thereof suppresses the differentiation of osteoclast precursor cells into osteoclasts and improves bone metabolism.
- the lactic acid bacterium Lactobacillus plantarum L-137 (hereinafter also referred to as "L-137 strain") has the same effect as the above-described immune cell culture supernatant. is not known.
- the culture supernatant of a culture obtained by culturing immune cells in the presence of lactic acid bacteria or a processed product thereof has an inhibitory effect on differentiation of osteoclast precursor cells into osteoclasts, bone metabolism It has been found that it has an improving action and/or an inhibitory action on bone density loss, preferably an inhibitory action on bone resorption properties in bone.
- the lactic acid bacterium Lactobacillus plantarum L-137 strain has the same effect as the culture supernatant of (1) above, and (3) the culture supernatant of (1) and (2) L- 137 strain was found to be useful for the treatment or prevention of osteoporosis and the like, and further studies were conducted to complete the present invention.
- the present invention is as follows.
- [1] A composition for suppressing the differentiation of osteoclast precursor cells into osteoclasts, characterized by containing a culture supernatant obtained by culturing immune cells in the presence of lactic acid bacteria or a processed product thereof, or a processed product thereof. thing.
- [2] A composition for improving bone metabolism, comprising a culture supernatant obtained by culturing immune cells in the presence of lactic acid bacteria or a processed product thereof, or a processed product thereof.
- [3] The composition according to [1] or [2] above, wherein the lactic acid bacterium belongs to the genus Lactobacillus.
- a composition for suppressing osteoclast differentiation of osteoclast precursor cells comprising Lactobacillus plantarum L-137 or a processed product thereof.
- a composition for suppressing differentiation of osteoclast progenitor cells into osteoclasts, improving bone metabolism and/or suppressing decrease in bone density comprising the following steps (a) to (c): Production method. (a) obtaining a culture by culturing immune cells in the presence of lactic acid bacteria or a processed product thereof; (b) obtaining a culture supernatant of immune cells or a processed product thereof, comprising removing lactic acid bacteria or a processed product thereof and immune cells from the culture obtained in step (a), and (c) step ( Step of mixing the culture supernatant obtained in b) or its processed material with a carrier and/or an excipient
- a composition for suppressing the differentiation of osteoclast precursor cells into osteoclasts a composition for improving bone metabolism and/or a composition for suppressing bone density loss, preferably a composition for preventing, improving or treating osteoporosis can provide things. Also, methods of making such compositions can be provided.
- Fig. 1 shows differentiation of osteoclast precursor cells into osteoclasts and bone resorption activity after 48 hours after addition of sRANKL (bone metabolism research reagent) and culture supernatant of immune cells to osteoclast precursor cells.
- FIG. 10 shows a graph evaluating inhibition.
- Fig. 2 shows differentiation of osteoclast precursor cells into osteoclasts and bone resorption activity after 72 hours of addition of sRANKL (bone metabolism research reagent) and culture supernatant of immune cells to osteoclast precursor cells.
- FIG. 10 shows a graph evaluating inhibition.
- Figure 3 shows the differentiation of osteoclast precursor cells into osteoclasts and suppression of bone resorption activity after 48 hours after adding sRANKL (reagent for bone metabolism research) and L-137 strain to osteoclast precursor cells.
- FIG. 4 shows the differentiation of osteoclast precursor cells into osteoclasts and suppression of bone resorption activity after 72 hours after addition of sRANKL (bone metabolism research reagent) and L-137 strain to osteoclast precursor cells. Shows the evaluated graph.
- FIG. 5 shows a graph evaluating the influence of the presence or absence of intake of L-137 strain-containing food on the standardized ultrasound propagation velocity (s-SOS) in the human calcaneus. The white graph indicates before the start of the test, and the colored graph indicates 3 months after taking the composition.
- the present invention contains an immune cell culture supernatant or a processed product thereof obtained by culturing a mixture of immune cells and lactic acid bacteria or a processed product thereof.
- progenitor cells of osteoclasts may be abbreviated as "osteoclast progenitor cells”.
- culture supernatant generally refers to a supernatant obtained by separating a culture obtained by culturing immune cells, for example, by centrifugation.
- Preferable centrifugation conditions include, but are not limited to, a temperature of 1 to 40°C, preferably 4 to 37°C, and a rotation speed of 2000 to 20000 rpm.
- lactic acid bacteria used in the present invention are not particularly limited, for example, lactic acid bacteria belonging to the genus Lactobacillus, Streptococcus, Enterococcus, Lactococcus, or Bifidus can be used. More specifically, Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus brevis, Lactobacillus casei, Lactobacillus fermentum , Lactobacillus paracasei, Lactobacillus buchneri, Lactobacillus delbrueckii, Lactobacillus rhamnosus, Streptococcus thermophilus, Enterococcus faecalis ( Enterococcus faecalis, Enterococcus faecium, Lactococcus lactis, Lactococcus plantarum or Bifidobacterium thermophilum, Bifidobacterium longum) or Bifidobacterium breve, but not limited thereto.
- immune cells are preferably cells including cells that can eat (phagocytose) the lactic acid bacteria described above, preferably of the genus Lactobacillus plantarum.
- Cells containing cells capable of consuming lactic acid bacteria, more preferably cells capable of consuming Lactobacillus plantarum L-137 is a cell containing
- the L-137 strain exposes more lipoteichoic acid to the cell surface than the lactic acid bacteria of the genus Lactobacillus commonly used in the field, such as the Lactobacillus plantarum JCM1149 strain. It is known to be easily eaten by seed cells (Int Immunopharmacol. 2015, 25(2) 321-331). Although the details are unknown, such properties of the L-137 strain may be useful for obtaining the effect of suppressing the differentiation of osteoclast precursor cells into osteoclasts or the effect of improving bone metabolism according to the present invention.
- Preferred immune cells for use in the present invention include, but are not limited to, cells including macrophages, natural killer (NK) cells, dendritic cells, B cells, and T cells.
- NK natural killer
- Commercially available immune cells may be used. Suitable examples of such commercially available products include, but are not limited to, products handled by iQ Bioscience's IQB-MSP103, Japan Charles River Co., Ltd., Japan Clea Co., Ltd., and the like.
- Preferred osteoclast progenitor cells used in the present invention include, for example, RANKL (receptor activator of NF- ⁇ B ligand), GM-CSF (Granulocyte Macrophage colony-stimulating factor), and other reagents to induce differentiation into osteoclasts.
- Cells derived from the cells are preferred, and examples thereof include, but are not limited to, primary cells such as bone marrow-derived monocytes, macrophage lineage progenitor cells, macrophage-like cells, and cell lines thereof.
- the culture temperature and culture time may be appropriately selected depending on the cells to be used, and are not particularly limited.
- the culture temperature is, for example, although not particularly limited, preferably 30 to 40 degrees, more preferably 35 to 37 degrees.
- the culture time is not particularly limited, but is preferably 24 to 96 hours, more preferably 48 to 72 hours.
- the medium used for culturing immune cells is not particularly limited, and for example, those containing inorganic salts, carbohydrates, amino acids, vitamins, proteins, peptides, fatty acids, lipids, serum and the like are preferably used.
- a commercially available product may be used.
- known synthetic general-purpose media preferably include, but are not limited to, RPMI1640, DMEM, MEM, MEM ⁇ , IMDM, McCoy's5A, and the like.
- the culture method and medium for osteoclast precursor cells the same ones as those for immune cells described above can be preferably used.
- the “processed product” of the immune cell culture supernatant is preferably a product obtained by purifying or processing the immune cell culture obtained by the method of the present invention and, if necessary, further centrifuging it. but not limited to these. Methods known in the art, such as gravity filtration, microfiltration, ultrafiltration, etc., may be used in purifying or processing the resulting culture. Preferable conditions for centrifugation include, but are not limited to, a temperature of 1 to 40° C., preferably 4 to 37° C., and a rotation speed of 2000 to 20000 rpm.
- the immune cell culture supernatant or treated product thereof of the present invention generally does not substantially contain the lactic acid bacteria used to obtain the culture supernatant, the treated product thereof, or the immune cells themselves.
- the culture supernatant of immune cells or a processed product thereof may be used as it is, or may be used in powder form by freeze-drying, low-temperature drying, spray-drying, L-drying, or a combination thereof. good too.
- the treated product may be diluted with an appropriate solvent (e.g., water, alcohol, organic solvent, etc.) and used, and may be used after adding an appropriate additive and processing such as gel or solid formulation. good too.
- the content of the immune cell culture supernatant or its processed product in the composition of the present invention is not particularly limited, but in 100% by mass of the composition, for example, in the range of about 0.1% to about 100% by mass and preferably in the range of about 5% to about 40% by weight.
- Lactobacillus plantarum L-137 strain Further, the present invention provides, as a different aspect from the above (1), lactic acid bacterium Lactobacillus plantarum L-137 (Accession number: FERM BP -08607), a composition for suppressing the differentiation of osteoclast precursor cells into osteoclasts and a composition for improving bone metabolism. Osteoclast precursor cells and immune cells are as described in (1) above.
- Lactobacillus plantarum L-137 strain (Lactobacillus plantarum L-137) used in the present invention is the National Institute of Advanced Industrial Science and Technology Patent Organism Depositary Center (now: National Institute of Technology and Evaluation Patent Organism Depository). Center; Address: Zip code 292-0818, Room 120, 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan), Accession number: FERM BP-08607 (FERM P deposited on November 30, 1995) -15317). It should be noted that mutants of Lactobacillus plantarum L-137 having the characteristics of Lactobacillus plantarum L-137 fall under the category of Lactobacillus plantarum L-137. In addition to Lactobacillus plantarum L-137 strain, other lactic acid bacteria may be contained in the composition of the present invention.
- the content of the Lactobacillus plantarum L-137 strain or its processed product in the composition of the present invention is not particularly limited, but is, for example, about 0.00% per 100% by mass of the composition. 0001 mass % to 0.1 mass %, preferably 0.005 to 0.05 mass %.
- Lactobacillus plantarum L-137 strain (Lactobacillus plantarum L-137) or its processed product of the present invention is, in the case of oral or injection administration, the age and weight of the ingestor, symptoms, administration time, It can be determined depending on the dosage form, administration method, drug combination, and the like.
- Lactobacillus plantarum L-137 strain per adult (about 60 kg) per day, Lactobacillus plantarum L-137 strain is preferably about 0.5 to 200 mg, more preferably about 1 to 100 mg, more preferably about 2 as dried dead cells. It is preferable to set up so that ⁇ 50 mg is taken.
- Lactobacillus plantarum L-137 is preferably about 5 ⁇ 10 8 to 2 ⁇ 10 11 cfu (Colony forming unit) per adult (about 60 kg) per day in terms of viable bacteria, and more Preferably, it is set to ingest about 1 ⁇ 10 9 to 1 ⁇ 10 11 cfu.
- the frequency of ingestion may be once a day or divided into multiple times.
- the amount of Lactobacillus plantarum L-137 strain or its processed product can be selected as appropriate.
- the above administration dose may be administered or applied in divided doses from once to several times per day.
- Lactobacillus plantarum L-137 strain and other lactic acid bacteria may be cultured in any medium such as natural medium, synthetic medium and semi-synthetic medium.
- lactic acid bacteria may be cultured according to a known method, a method known per se, or a method analogous thereto.
- the medium is not particularly limited, and for example, one containing a nitrogen source and/or a carbon source is preferably used.
- the nitrogen source is not particularly limited, and examples thereof include meat extract, peptone, gluten, casein, yeast extract, amino acids, and the like.
- the carbon source is not particularly limited, and examples thereof include glucose, xylose, fructose, inositol, maltose, starch syrup, koji juice, starch, bagasse, wheat bran, molasses, and glycerin. These may be used alone or in combination of two or more.
- the medium may further contain minerals.
- the inorganic substance is not particularly limited, and examples thereof include ammonium sulfate, potassium phosphate, magnesium chloride, salt, iron, manganese, molybdenum, and various vitamins. may
- the culture temperature and culture time of Lactobacillus plantarum L-137 strain (Lactobacillus plantarum L-137) and other lactic acid bacteria are not particularly limited as long as the culture can be carried out efficiently. may be, for example, usually about 25 to 40° C., preferably about 27 to 35° C., and the culture time may be, for example, about 12 to 48 hours. Moreover, in one aspect of the present invention, lactic acid bacteria may be cultured by aeration shaking. Also, the pH of the medium is not particularly limited, but in one embodiment of the present invention, it may be generally about pH 3-6, preferably about pH 4-6.
- Lactobacillus plantarum L-137 strain (Lactobacillus plantarum L-137) and other lactic acid bacterium "processed product” is preferably a processed product of the lactic acid bacterium or a culture of the lactic acid bacterium, but limited to these not.
- the bacteria may be viable or dead, but from the viewpoint of stability and ease of handling, it is preferable to use dead cells. This dead cell is also included in the processed product of lactic acid bacteria.
- such a processed product may be used as it is, or may be used in the form of powder by freeze-drying, low-temperature drying, spray-drying, L-drying, or a combination thereof.
- these treated products may be used after being diluted with an appropriate solvent (water, alcohol, organic solvent, etc.), or may be used after adding an appropriate additive to form a gel or solid.
- a method for preparing dead cells of Lactobacillus plantarum L-137 and other lactic acid bacteria will be specifically described below.
- the method for preparing the dead cells is not particularly limited as long as the effects of the present invention are not lost.
- a method of sterilizing the cells to make them dead (II) sterilizing the live cells of lactic acid bacteria in a culture solution to make them dead, and then removing the dead cells from the culture solution. It may be prepared by any method such as a method of separation.
- a variety of methods commonly used in this field may be employed as the method for isolating the bacterial cells from the culture solution, and is not particularly limited.
- a method of separating the culture solution and the bacterial cells by removing the supernatant from the culture solution by means of centrifugation or the like may be employed.
- the separation operation may include a filtration step.
- the sterilization method is not particularly limited, and examples thereof include heat treatment, ultraviolet irradiation, formalin treatment, and the like.
- the sterilization treatment may be performed on the collected viable cells or on the culture solution containing the viable cells.
- the heating temperature is not particularly limited, but may be, for example, usually about 60 to 100 degrees (°C), preferably about 70 to 90 degrees.
- the heating means a known method can be used, and there is no particular limitation.
- means such as a heater may be used.
- the heating time is not particularly limited as long as the sterilization treatment can be sufficiently completed.
- the heating time may be usually about 5 to 40 minutes, preferably about 10 to 30 minutes after reaching the desired temperature.
- the dead cells obtained as described above may be further subjected to grinding, crushing, freeze-drying, or the like to obtain a treated dead cell.
- the treated dead cells can also be suitably used as dead cells.
- composition of the present invention is characterized by having an effect of suppressing the differentiation of osteoclast precursor cells into osteoclasts and/or an effect of improving bone metabolism.
- the composition is useful for osteoporosis, osteogenesis imperfecta, hypercalcemia, osteomalacia, ostecalcification, osteolytic bone disease, osteonecrosis, rheumatoid arthritis, osteoarthritis, inflammatory arthritis, bone marrow
- the composition is used for the prevention, improvement or treatment of bone loss, bone fracture, or lumbago due to inflammation, cancer, aging, etc., or the prevention, improvement or treatment of osteoporosis, rheumatoid arthritis or bone fracture.
- the composition is used for prevention, amelioration, or treatment of osteoporosis, but is not limited to these cases.
- Another or further preferable example of the composition of the present invention includes, but is not limited to, a composition having a bone mineral density reduction inhibitory effect.
- compositions of the present invention are for food and drink and/or pharmaceuticals (including veterinary drugs).
- the composition of the present invention is used as an additive for food and drink.
- Compositions for food and drink, food and drink additives, or pharmaceuticals are the above-described culture supernatant of the present invention or its processed product, or the L-137 strain or its processed product and a pharmaceutically acceptable A carrier, an additive and the like can be appropriately blended to form a formulation or the like. Formulation methods and formulation techniques for this purpose have been well established in the past, and may be followed.
- oral agents such as tablets, coated tablets, pills, powders, granules, capsules, liquids, suspensions, emulsions, injections, infusions, suppositories, ointments
- Parenteral agents such as patches
- the mixing ratio of the carrier or additive may be appropriately set based on the range normally employed in the food and beverage, pharmaceutical, or veterinary fields.
- Pharmaceutically acceptable carriers or additives are not particularly limited, but examples of carriers include various carriers such as aqueous or oily bases, and examples of aqueous carriers include water, physiological saline, and ethanol. , glycerin, polyethylene glycol, propylene glycol, methylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, polyacrylic acid, polysaccharide gum-based natural polymers, etc.
- oily carriers include petrolatum, squalane, Suitable oils such as paraffin, waxes and the like include, but are not limited to.
- additives include enzymes, pH adjusters, preservatives, bactericides, antioxidants, antifungal agents, shelf life improvers, bleaches, brighteners, flavors, sweeteners, acidulants, seasonings, and bitterness.
- composition of the present invention when used for food and drink, such food and drink include health foods, foods with function claims, foods for specified health uses, and foods for the sick.
- the form of food and drink is not particularly limited, but specific examples include tablets, granules, powders, and drinks as so-called nutritional supplements or supplements.
- drinks such as tea drinks, soft drinks, carbonated drinks, nutritional drinks, fruit drinks, lactic acid drinks, noodles such as soba noodles, udon noodles, Chinese noodles, instant noodles, candies, candies, gums, chocolates, snacks , biscuits, jellies, jams, creams, baked sweets, breads and other sweets and breads, processed marine and livestock foods such as ham, sausages, hanpen, fish cakes, processed milk, fermented milk and other dairy products, salad oil, tempura oil, Oils and fats such as margarine, mayonnaise, shortening, whipped cream, and dressings; seasonings such as sauces and sauces; retort pouch foods such as curries, stews, rice bowls, rice porridge and porridge; can include, but are not limited to.
- composition of the present invention may contain any component known in the fields of medicine, pharmacy, veterinary medicine, animal husbandry, feed or food, as long as the effects of the present invention are not lost.
- the method for confirming the effect of suppressing the differentiation of osteoclast precursor cells to osteoclasts and/or the effect of improving bone metabolism is, for example, TRAP (tartaric acid resistance after addition of RANKL (receptor activator of NF- ⁇ B ligand) reagent) and methods for evaluating tartrate-resistant acid phosphatase activity.
- RANKL known as a differentiation-inducing signal, binds to a receptor (RANK) on the plasma membrane of osteoclast precursors and induces differentiation into osteoclasts.
- RANKL known as a differentiation-inducing signal
- osteoclasts exhibit strong TRAP activity in the cytoplasm, differentiation into osteoclasts can be confirmed by evaluating TRAP activity after addition or administration of RANKL.
- the TRAP activity here can be said to be an indicator of the differentiation of osteoclast precursor cells into osteoclasts, and suppression of TRAP activity is thought to suppress bone destruction and improve bone metabolism. It is also considered to be effective in confirming the presence or absence of suppression of osteoporosis.
- "improved bone metabolism” means, for example, that the balance between bone formation and bone resorption in vivo becomes more favorable.
- evaluation may be performed according to well-established methods in the relevant field, such as a method of detection and quantification using an enzymatic reaction), bone resorption assay (pit formation assay), and the like. As an example of these methods, reference can be made to the examples below.
- the culture supernatant of the present invention or its processed product or Lactobacillus plantarum L-137 strain (Lactobacillus plantarum L-137) or A composition containing the treated product is confirmed to be superior in suppressing bone mineral density decrease compared to a composition containing neither the culture supernatant or the treated product, nor the L-137 strain or the processed product thereof. method.
- the method for confirming the effect of suppressing bone density reduction is, for example, the ultrasonic wave propagation distance per unit time (m / sec), that is, the ultrasonic wave propagation speed in the bone (Speed Of Sound, SOS).
- This method has no exposure to radiation and has the advantage that even pregnant women and children can be measured.
- SOS is usually measured at the calcaneus, and has a strong correlation with bone density at sites such as the calcaneus that contain a large amount of cancellous bone. If the SOS value is high, the bone density is high.
- SOS has different definitions and standard values depending on the measurement model and its manufacturer, and the standardized ultrasonic propagation velocity (standardized-SOS: s-SOS) is also used to ensure compatibility of measurement values between models. .
- standardized-SOS s-SOS
- Benus evo manufactured by Shibuya Kogyo Co., Ltd.
- Other devices known in the art can also be used.
- most of the bone strength (approximately 70%) can be explained by bone density alone, and this method is also effective for confirming whether or not osteoporosis is suppressed.
- the above-mentioned SOS method is classified as a quantitative ultrasound measurement method (QUS), and there are other methods such as measuring the attenuation coefficient (BUA: broadband ultrasound attenuation). It can be used for evaluation of the composition of the invention.
- known bone density measurement methods other than the above such as DEA (dual energy X ray absorptiometry) method, MD (microdensitometry) method, RA (radiographic absorptiometry) method, quantitative CT (QCT) measurement method, etc.
- DEA dual energy X ray absorptiometry
- MD microdensitometry
- RA radiographic absorptiometry
- QCT quantitative CT
- the instruction manual or its packaging box may indicate that the composition has an effect of suppressing the differentiation of osteoclast precursor cells into osteoclasts and an effect of improving bone metabolism.
- the culture supernatant or its processed product is preferably about 0.1 to 100% by weight, more preferably about 5 to 60% by weight, more preferably about It is preferably contained in an amount of 20 to 40% by weight.
- the Lactobacillus plantarum L-137 strain (Lactobacillus plantarum L-137) or its processed product is preferably about 0.001 to 10% by weight, based on the total amount of the composition, More preferably about 0.01 to 1% by weight, still more preferably about 0.05 to 0.5% by weight.
- the present invention preferably comprises the following steps (a) to (c), a method for producing a composition for suppressing differentiation of osteoclast precursor cells into osteoclasts and/or improving bone metabolism, including.
- step (a) obtaining a culture by culturing immune cells in the presence of lactic acid bacteria or a processed product thereof; (b) obtaining a culture supernatant of immune cells or a processed product thereof, comprising removing lactic acid bacteria or a processed product thereof and immune cells from the culture obtained in step (a), and (c) step ( Step of mixing the culture supernatant obtained in b) or its processed material with a carrier and/or an excipient
- the immune cells are not particularly limited, but the immune cells are lactic acid bacteria or a processed product thereof (preferably L -137 strain) is preferred.
- a preferred example of removing lactic acid bacteria or a processed product thereof and immune cells from the mixture obtained in step (a) is, from the mixture, a method known in the art such as centrifugation. , but not limited to, removing lactic acid bacteria or processed products thereof and immune cells.
- aqueous carriers include water, physiological saline, ethanol, glycerin, polyethylene glycol, propylene glycol, methylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, polyacrylic acid, polysaccharide gum-based natural polymers.
- oily carriers include, but are not limited to, suitable oils and waxes such as petrolatum, squalane and paraffin.
- step (c) preferred excipients used in the above step (c) have been well established in the food or pharmaceutical fields, and the present invention may follow them.
- lactose, sucrose, mannitol, corn starch , powdered cellulose, calcium hydrogen phosphate, calcium carbonate and the like can be preferably used, but are not limited to these.
- the composition of the present invention except that the culture supernatant of the present invention or its processed product, or Lactobacillus plantarum L-137 strain (Lactobacillus plantarum L-137) or its processed product is added to the composition, It can be appropriately processed and manufactured by a general composition manufacturing method. That is, the present invention further includes a method for producing a composition comprising the step of mixing the culture supernatant or its treated material, and optionally other ingredients. Alternatively, the present invention includes a method for producing a composition comprising the step of mixing Lactobacillus plantarum L-137 or a processed product thereof, and optionally other ingredients. .
- each component is It is preferable to mix or stir by a known method or a method known per se so as to achieve uniformity. Methods of mixing or stirring are well established in the art and may be followed.
- Step of inducing differentiation of osteoclast precursor cells into osteoclasts Evaluation of osteoclast differentiation using osteoclast precursor cell RAW264.7 (ECACC strain number 91062702; DS Pharma Biomedical Co., Ltd.), a mouse-derived monocytic leukemia cell line that is induced to osteoclasts only by RANKL. gone.
- Osteoclast precursor RAW264.7 cells were suspended in 10% FBS-containing MEM ⁇ medium at 7.0 ⁇ 10 4 cells/mL, and 50 ⁇ L of each suspension was added to a 96-well culture plate (3,500 cells/well). Further, sRANKL (Product No.
- the final concentration of sRANKL is 100 ng / mL
- the ratio of immune cell culture supernatant is 6.25%, 12.5%, 37.5% (v / v)
- differentiation induction culture is performed in a 5% CO 2 incubator at 37 ° C for 48 hours, 72 hours went.
- TRAP activity measurement step After the differentiation-inducing culture, the supernatant was removed, and 100 ⁇ L of a fixing solution prepared by mixing acetone and ethanol at a ratio of 1:1 was added to the 96-well culture plate containing the cells. After 1 minute, the fixative was removed and air-dried for 30 minutes. Thereafter, the TRAP solution kit (product number NIB 47249000; Oriental Yeast) was operated, and the absorbance was measured at 415 nm using a plate reader.
- a fixing solution prepared by mixing acetone and ethanol at a ratio of 1:1
- Results The evaluation results are shown in Table 1 and Figures 1 and 2 below. After culturing for 48 hours and after culturing for 72 hours, the culture supernatant of the immune cells obtained above exhibited a concentration-dependent inhibitory effect on differentiation of osteoclast precursor cells into osteoclasts and an inhibitory effect on bone resorption in bone. Indicated.
- Osteoclast differentiation induction step Evaluation of osteoclast differentiation using osteoclast precursor cell RAW264.7 (ECACC strain number 91062702; DS Pharma Biomedical Co., Ltd.), a mouse-derived monocytic leukemia cell line that is induced to osteoclasts only by RANKL. gone.
- Osteoclast precursor RAW264.7 cells were suspended in 10% FBS-containing MEM ⁇ medium at 7.0 ⁇ 10 4 cells/mL, and 50 ⁇ L of each suspension was added to a 96-well culture plate (3,500 cells/well).
- sRANKL Product No. 47187000; Oriental Yeast Co., Ltd.
- MEM ⁇ medium containing 10% FBS was diluted to 267 ng/mL with MEM ⁇ medium containing 10% FBS, and 75 ⁇ L each was added to the 96-well culture plate to which the RAW264.7 cells were added.
- dead cells of Lactobacillus plantarum L-137 were suspended in 10% FBS-containing MEM ⁇ medium to 134 ng/mL, 1.34 ⁇ g/mL, and 13.4 ⁇ g/mL, Each 75 ⁇ L of the RAW264.7 cells was added to the 96-well culture plate to make the total volume 200 ⁇ L.
- the final concentration of sRANKL was 100 ng/mL
- the final concentrations of L-137 dead cells were 50 ng/mL, 500 ng/mL, and 5 ⁇ g/mL
- the differentiation-inducing culture was performed at 37°C in a 5% CO 2 incubator. , went 48 hours, 72 hours.
- TRAP activity measurement step After the differentiation-inducing culture, the supernatant was removed, and 100 ⁇ L of a fixing solution prepared by mixing acetone and ethanol at a ratio of 1:1 was added to the 96-well culture plate containing the cells. After 1 minute, the fixative was removed and air-dried for 30 minutes. Thereafter, the TRAP solution kit (product number NIB 47249000; Oriental Yeast) was operated, and the absorbance was measured at 415 nm using a plate reader.
- a fixing solution prepared by mixing acetone and ethanol at a ratio of 1:1
- composition used As the composition of the present invention, a commercially available tablet containing 10 mg of heat-treated Lactobacillus plantarum L-137 strain per tablet (300 mg) (product name: Mamori Kaoru Lactobacillus L-137 Supplement) was used. . Although the tablet contains components other than strain L-137 (lactose, starch, sucrose fatty acid ester, etc.), these components do not particularly affect the following experiments.
- compositions (1) and (2) are useful as a prophylactic/therapeutic agent for osteoporosis, food and drink, feed, pharmaceutical or quasi-drug, cosmetics, and the like.
Abstract
Description
一方、乳酸菌には、免疫賦活作用等があることが知られている(特許文献2)。
[1]乳酸菌又はその処理物の存在下に免疫細胞を培養して得られる培養上清又はその処理物を含有することを特徴とする、破骨前駆細胞の破骨細胞への分化抑制用組成物。
[2]乳酸菌又はその処理物の存在下に免疫細胞を培養して得られる培養上清又はその処理物を含有することを特徴とする、骨代謝改善用組成物。
[3]乳酸菌がラクトバチルス(Lactobacillus)属の菌であることを特徴とする、前記[1]又は[2]に記載の組成物。
[4]乳酸菌がラクトバチルス・プランタラム L-137株(Lactobacillus plantarum L-137)であることを特徴とする、前記[1]~[3]のいずれかに記載の組成物。
[5]ラクトバチルス・プランタラム L-137株(Lactobacillus plantarum L-137)又はその処理物を含有することを特徴とする、破骨前駆細胞の破骨細胞への分化抑制用組成物。
[6]ラクトバチルス・プランタラム L-137株(Lactobacillus plantarum L-137)又はその処理物を含有することを特徴とする、骨代謝改善用組成物。
[7]骨粗鬆症の予防、改善及び/又は治療用であることを特徴とする、前記[1]~[6]のいずれかに記載の組成物。
[8]骨密度低下抑制用であることを特徴とする、前記[1]~[7]のいずれか1項に記載の組成物。
[9]以下の工程(a)~(c)を含むことを特徴とする、破骨前駆細胞の破骨細胞への分化抑制用、骨代謝改善用及び/又は骨密度低下抑制用組成物の製造方法。
(a)乳酸菌又はその処理物の存在下に免疫細胞を培養して培養物を得る工程、
(b)工程(a)で得られた培養物から、乳酸菌又はその処理物及び免疫細胞を除去することを含む、免疫細胞の培養上清又はその処理物を得る工程、及び
(c)工程(b)で得られた培養上清又はその処理物と、担体及び/又は賦形剤とを混合する工程
本発明は、免疫細胞と乳酸菌又はその処理物の混合物の培養により得られる免疫細胞の培養上清又はその処理物を含有し、好ましくは、培養上清を得るために用いた該乳酸菌又はその処理物自体は実質的に含まないことを特徴とする、破骨前駆細胞の破骨細胞への分化抑制用組成物及び骨の骨代謝改善用組成物、特に好ましくは、骨吸収抑制用組成物を含む。
なお、本明細書において、破骨細胞の前駆細胞を、「破骨前駆細胞」と略称することもある。また、本明細書において、「培養上清」とは、通常、免疫細胞を培養して得られる培養物を、例えば、遠心分離によって分離した上澄み液のことである。好ましい遠心分離の条件としては、例えば、1~40度、好ましくは、4~37度の温度、2000~20000rpmの回転数等が挙げられるが、これらに限定されない。
なお、破骨前駆細胞の培養方法及び培地についても、上記した免疫細胞と同様のものを好ましく用いることが出来る。
さらに本発明は、上記(1)とは別の態様として、乳酸菌ラクトバチルス・プランタラムL-137株(Lactobacillus plantarum L-137、受託番号:FERM BP-08607号)を含有することを特徴とする、破骨前駆細胞の破骨細胞への分化抑制用組成物及び骨代謝改善用組成物を含む。
破骨前駆細胞及び免疫細胞については、上記(1)で説明した通りである。
[乳酸菌の培養]
本発明において、ラクトバチルス・プランタラムL-137株(Lactobacillus plantarum L-137)及び他の乳酸菌は、天然培地、合成培地及び半合成培地等の培地で培養したものいずれであってもよい。本発明において、乳酸菌の培養は、公知方法、自体公知の方法又はそれらに準じる方法に従って行われてよい。
前記培地は、前記窒素源及び/又は炭素源に加えて、さらに、無機質を添加してもよい。前記無機質としては、特に限定されず、例えば、硫酸アンモニウム、リン酸カリウム、塩化マグネシウム、食塩、鉄、マンガン、モリブデン又は各種ビタミン類等が挙げられ、これらを1種で又は2種以上を組合せて用いてもよい。
ラクトバチルス・プランタラムL-137株(Lactobacillus plantarum L-137)及び他の乳酸菌の「処理物」とは、好ましくは、当該乳酸菌を加工したもの又は当該乳酸菌の培養物であるが、これらに限定されない。また、菌は、生菌でもよく、死菌体でもよいが、安定性及び取扱いの容易性等の観点から、死菌体を用いることが好ましい。この死菌体も、乳酸菌の処理物に含まれる。
本発明において、前記死菌体の調製方法は、本発明の効果を失しない限り、特に限定されないが、例えば、(I)培養終了後に乳酸菌の生菌体を培養液から分離した後に、前記生菌体を殺菌処理して死菌体の状態とする方法、(II)培養液中で乳酸菌の生菌体を殺菌処理して死菌体の状態とし、その後に前記死菌体を培養液から分離する方法等のいずれの方法によって調製してもよい。
本発明の組成物は、破骨前駆細胞の破骨細胞への分化抑制作用及び/又は骨代謝改善作用を有することを特長とする。好ましくは、組成物が、骨粗鬆症、骨形成不全、高カルシウム血症、骨軟化症、骨石灰脱失症、骨溶解性骨疾患、骨壊死、関節リウマチ、変形性関節症、炎症性関節炎、骨髄炎、癌又は加齢等による骨の喪失、骨折、又は腰痛の予防、改善又は治療に用いられる場合であり、より好ましくは、組成物が、骨粗鬆症、関節リウマチ、又は骨折の予防、改善又は治療に用いられる場合であり、さらに好ましくは、組成物が、骨粗鬆症の予防、改善又は治療に用いられる場合であるが、これらの場合に限定されない。別の、あるいは、さらなる本発明の組成物の好ましい例としては、組成物が骨密度低下抑制作用を有する組成物が挙げられるが、これに限定されない。
飲食品用、飲食品用添加剤用又は医薬品用である組成物は、上記した本発明の培養上清又はその処理物、あるいは、L-137株又はその処理物とさらに薬学的に許容される担体、添加剤等を適宜配合して製剤化等することができる。そのための製剤化方法や製剤化技術は従来十分に確立されているので、それに従ってよい。例えば、医薬品用の場合、具体的には、錠剤、被覆錠剤、丸剤、散剤、顆粒剤、カプセル剤、液剤、懸濁剤、乳剤等の経口剤、注射剤、輸液、坐剤、軟膏、パッチ剤等の非経口剤とすることができる。担体または添加剤の配合割合については、飲食品、医薬品又は獣医学分野において通常採用されている範囲に基づいて適宜設定すればよい。
添加剤の例としては、酵素、pH調整剤、保存料、殺菌料、酸化防止剤、防カビ剤、日持向上剤、漂白剤、光沢剤、香料、甘味料、酸味料、調味料、苦味料、乳化剤、増粘剤、安定剤、ゲル化剤、糊料、賦形剤、結合剤、崩壊剤、滑沢剤、着色剤、矯味剤、香料等が挙げられるが、これらに限定されない。これらに関する技術は、従来十分に確立されているので、本発明において、それらに従ってよい。
さらに、本発明の組成物には、本発明の効果を失しない限り、例えば、医学、薬学、獣医学、畜産、飼料又は食品等の分野で知られる任意の成分が含有されていてもよい。
本発明の組成物の効果を確認する方法としては、例えば、本発明の培養上清又はその処理物、あるいは、ラクトバチルス・プランタラムL-137株(Lactobacillus plantarum L-137)又はその処理物を含有する組成物が、培養上清又はその処理物、あるいは、L-137株又はその処理物のいずれも含有しない組成物に比べて、破骨前駆細胞の破骨細胞への分化抑制活性及び/又は骨代謝改善活性に優れることを確認する方法が挙げられる。
これらの方法の一例として、後述の実施例を参照することができる。
本発明の組成物の骨密度低下抑制効果を確認する方法としては、例えば、本発明の培養上清又はその処理物、あるいは、ラクトバチルス・プランタラムL-137株(Lactobacillus plantarum L-137)又はその処理物を含有する組成物が、培養上清又はその処理物、あるいは、L-137株又はその処理物のいずれも含有しない組成物に比べて、骨密度低下抑制作用に優れることを確認する方法が挙げられる。
具体的には、骨密度低下抑制効果の確認方法は、例えば、単位時間当たりの超音波伝播距離(m/sec)、すなわち、骨内における超音波伝播速度(Speed Of Sound、SOS)、を測定する方法が挙げられる。
本方法は、被曝がなく、妊婦や子供でも測定できる利点がある。SOSは、通常、踵骨で測定され、踵骨のような海綿骨を多く含む部位の骨密度と強い相関を有する。SOSの値が大きい場合、骨密度は高い。SOSは測定機種やその製造会社ごとに定義や基準値が異なり、機種間の測定値の互換性を確保するため、標準化された超音波伝播速度(standardized-SOS:s-SOS)も使用される。本発明においては、例えば、Benus evo (澁谷工業株式会社製)を用いることが出来るが、当分野で公知の他の機器を用いることも出来る。なお、骨密度のみで骨強度のほとんど(約7割程度)が説明出来るとする説もあり、本方法は、骨粗鬆症の抑制の有無の確認にも有効である。
上記したSOS法は、定量的超音波測定法(QUS: quantitative ultrasound)に分類され、他に、減衰係数 (BUA: broadband ultrasound attenuation)を測定する方法等もあり、SOS法以外のQUS法も本発明の組成物の評価等に用いることが出来る。また、上記以外の公知の骨密度測定方法、例えば、DEA (dual energy X ray absorptiometry) 法、MD (microdensitometry) 法、RA (radiographic absorptiometry) 法、定量的CT(QCT)測定法等を用いてもよく、上記した踵骨の代わりに、あるいは、踵骨と合わせて、大腿骨、脊椎、橈骨等の部位が測定されてもよいが、これらに限定されない。
また、本発明の組成物において、ラクトバチルス・プランタラムL-137株(Lactobacillus plantarum L-137)又はその処理物は、組成物の全量に対し、好ましくは、約0.001~10重量%、より好ましくは、約0.01~1重量%、さらに好ましくは、約0.05~0.5重量%含まれることが好ましい。
本発明は、好ましくは、以下の工程(a)~(c)を含むことを特徴とする、破骨前駆細胞の破骨細胞への分化抑制用及び/又は骨代謝改善用組成物の製造方法を含む。
(a)乳酸菌又はその処理物の存在下に免疫細胞を培養して培養物を得る工程、
(b)工程(a)で得られた培養物から、乳酸菌又はその処理物及び免疫細胞を除去することを含む、免疫細胞の培養上清又はその処理物を得る工程、及び
(c)工程(b)で得られた培養上清又はその処理物と、担体及び/又は賦形剤とを混合する工程
試験方法:<1.培養上清を得る工程>
免疫細胞(日本クレア株式会社より購入したマウス由来脾臓細胞)を5.0×106 cells/mLとなるように10%FBS含有RPMI1640培地に懸濁し、免疫細胞懸濁液とした。ラクトバチルス・プランタラムL-137死菌体が1000ng/mLとなるように10%FBS含有RPMI1640で懸濁し、免疫細胞刺激用検液とした。免疫細胞刺激用検液と免疫細胞懸濁液を100μLずつ、96well培養プレートに添加し(免疫細胞終濃度:2.5×106 cells/mL、菌体終濃度:500ng/mL)、5%CO2インキュベータ内で37℃、24時間培養し、上清を得た。得られた上清に対し遠心分離(条件:20℃、2,000rpm、20min)を行い、L-137株と免疫細胞を除去した培養上清を得た。
RANKLのみで破骨細胞に誘導される、マウス由来単球白血病細胞株である破骨細胞前駆細胞RAW264.7(ECACC株番号91062702;DSファーマバイオメディカル株式会社)を用いて破骨細胞分化評価を行った。破骨前駆細胞RAW264.7細胞を10%FBS含有MEMα培地で7.0×104cells/mLとなるように懸濁し、96well培養プレートに50μLずつ添加した(3,500cells/well)。さらに、sRANKL(製品番号47187000;オリエンタル酵母工業株式会社)を10%FBS含有MEMα培地で267ng/mLに希釈して、上記したRAW264.7細胞を添加した96well培養プレートに75μLずつ添加した。さらにL-137で刺激した免疫細胞の培養上清を12.5μL、25μL、75μL添加した。培養上清を12.5μL添加したwellには62.5μLの10%FBS含有MEMα培地を、培養上清を25μL添加したwellには50μLの10%FBS含有MEMα培地を添加し、全量を200μLとした。すなわちsRANKLの終濃度は100ng/mL、免疫細胞の培養上清割合は6.25%,12.5%,37.5%(v/v)として、分化誘導培養を5%CO2インキュベータ内で37℃、48時間、72時間行った。
分化誘導培養後、上清を除去し、アセトンとエタノールを1:1の割合で混合した固定液を100μLずつ細胞の入った96well培養プレートに添加した。1分経過後に固定液を除き、30分風乾させた。その後はTRAP solution kit(製品番号 NIB 47249000;オリエンタル酵母)に従い操作し、プレートリーダーを用いて415nmで吸光度を測定した。
試験方法:<1.破骨細胞分化誘導工程>
RANKLのみで破骨細胞に誘導される、マウス由来単球白血病細胞株である破骨細胞前駆細胞RAW264.7(ECACC株番号91062702;DSファーマバイオメディカル株式会社)を用いて破骨細胞分化評価を行った。破骨前駆細胞RAW264.7細胞を10%FBS含有MEMα培地で7.0×104cells/mLとなるように懸濁し、96well培養プレートに50μLずつ添加した(3,500cells/well)。さらに、sRANKL(製品番号47187000;オリエンタル酵母工業株式会社)を10%FBS含有MEMα培地で267ng/mLに希釈して、上記したRAW264.7細胞を添加した96well培養プレートに75μLずつ添加した。さらにラクトバチルス・プランタラムL-137株(Lactobacillus plantarum L-137)の死菌体を10%FBS含有MEMα培地で134 ng/mL, 1.34 μg/mL, 13.4 μg/mLとなるように懸濁し、RAW264.7細胞を添加した96well培養プレートに75μLずつ添加し、全量を200μLとした。すなわちsRANKLの終濃度は100 ng/mL、L-137死菌体の終濃度は50 ng/mL, 500 ng/mL, 5 μg/mLとして、分化誘導培養を5%CO2インキュベータ内で37℃、48時間、72時間行った。
分化誘導培養後、上清を除去し、アセトンとエタノールを1:1の割合で混合した固定液を100μLずつ細胞の入った96well培養プレートに添加した。1分経過後に固定液を除き、30分風乾させた。その後はTRAP solution kit(製品番号 NIB 47249000;オリエンタル酵母)に従い操作し、プレートリーダーを用いて415nmで吸光度を測定した。
試験方法:<1.使用した組成物>
本発明の組成物として、1錠 (300 mg)当たり、加熱処理されたラクトバチルス・プランタラム L-137株を10 mg含む市販の錠剤(製品名:まもり高める乳酸菌L-137 サプリメント)を用いた。錠剤には、L-137株以外の成分(乳糖、デンプン、ショ糖脂肪酸エステル等)も含まれているが、これらの成分は以下の実験に特に影響しない。
40~73歳の男女31名の被験者を2群に分けた(非摂取群:10名、L-137株摂取群:21名)。L-137株摂取群にはL-137株を含有する上記組成物を1日1錠で3ヶ月間摂取させた。
試験開始前及び組成物摂取3ヶ月後に各被験者の踵骨にて、s-SOSを測定した。被験者の片足踵周辺をエタノールで洗浄し、超音波検査用ゼリーを十分に塗布した。ゼリーが馴染んだ後、被験者の踵を装置計測部に挿入して、測定し、s-SOSを得た。
被験者の踵骨のs-SOS 評価には、Benus evo (澁谷工業株式会社製)を用いて行った。
上記結果から、本発明の乳酸菌L-137株を含有する組成物が、骨密度低下抑制作用を示すことが明らかとなった。なお、L-137株の代わりに、試験例1の方法で得られた培養上清やその処理物を用いた組成物を用いた場合にも、同様の効果が期待できる。
Claims (9)
- 乳酸菌又はその処理物の存在下に免疫細胞を培養して得られる培養上清又はその処理物を含有することを特徴とする、破骨前駆細胞の破骨細胞への分化抑制用組成物。
- 乳酸菌又はその処理物の存在下に免疫細胞を培養して得られる培養上清又はその処理物を含有することを特徴とする、骨代謝改善用組成物。
- 乳酸菌がラクトバチルス(Lactobacillus)属の菌であることを特徴とする、請求項1又は2に記載の組成物。
- 乳酸菌がラクトバチルス・プランタラム L-137株(Lactobacillus plantarum L-137)であることを特徴とする、請求項1~3のいずれか1項に記載の組成物。
- ラクトバチルス・プランタラム L-137株(Lactobacillus plantarum L-137)又はその処理物を含有することを特徴とする、破骨前駆細胞の破骨細胞への分化抑制用組成物。
- ラクトバチルス・プランタラム L-137株(Lactobacillus plantarum L-137)又はその処理物を含有することを特徴とする、骨代謝改善用組成物。
- 骨粗鬆症の予防、改善及び/又は治療用であることを特徴とする、請求項1~6のいずれか1項に記載の組成物。
- 骨密度低下抑制用であることを特徴とする、請求項1~7のいずれか1項に記載の組成物。
- 以下の工程(a)~(c)を含むことを特徴とする、破骨前駆細胞の破骨細胞への分化抑制用、骨代謝改善用及び/又は骨密度低下抑制用組成物の製造方法。
(a)乳酸菌又はその処理物の存在下に免疫細胞を培養して培養物を得る工程、
(b)工程(a)で得られた培養物から、乳酸菌又はその処理物及び免疫細胞を除去することを含む、免疫細胞の培養上清又はその処理物を得る工程、及び
(c)工程(b)で得られた培養上清又はその処理物と、担体及び/又は賦形剤とを混合する工程
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280032086.9A CN117279521A (zh) | 2021-05-17 | 2022-03-22 | 用于抑制破骨前体细胞分化为破骨细胞的组合物及用于改善骨代谢的组合物 |
JP2023522277A JPWO2022244447A1 (ja) | 2021-05-17 | 2022-03-22 | |
EP22804365.9A EP4342535A1 (en) | 2021-05-17 | 2022-03-22 | Composition for inhibition of differentiation of osteoclast precursor cells into osteoclasts, and composition for improving bone metabolism |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021083347 | 2021-05-17 | ||
JP2021-083347 | 2021-05-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022244447A1 true WO2022244447A1 (ja) | 2022-11-24 |
Family
ID=84141538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/013051 WO2022244447A1 (ja) | 2021-05-17 | 2022-03-22 | 破骨前駆細胞の破骨細胞への分化抑制用組成物及び骨代謝改善用組成物 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP4342535A1 (ja) |
JP (1) | JPWO2022244447A1 (ja) |
CN (1) | CN117279521A (ja) |
TW (1) | TW202313077A (ja) |
WO (1) | WO2022244447A1 (ja) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11228425A (ja) * | 1998-02-13 | 1999-08-24 | Takeda Food Products Ltd | Il−12産生誘導組成物 |
JP2010006801A (ja) | 2008-05-30 | 2010-01-14 | Bio Medical Research Group:Kk | 乳酸菌配合物及びその製造方法 |
JP2010095465A (ja) * | 2008-10-16 | 2010-04-30 | House Wellness Foods Kk | 乳酸菌含有免疫賦活用組成物 |
JP2010235534A (ja) | 2009-03-31 | 2010-10-21 | Fancl Corp | 骨粗鬆症の予防又は治療用剤 |
JP2015096476A (ja) * | 2013-11-15 | 2015-05-21 | 株式会社東洋新薬 | コラーゲン産生促進用組成物、コラーゲン吸収促進用組成物、抗肥満用組成物 |
JP2017114814A (ja) * | 2015-12-24 | 2017-06-29 | 丸善製薬株式会社 | 化粧料 |
WO2019045037A1 (ja) * | 2017-09-01 | 2019-03-07 | ハウスウェルネスフーズ株式会社 | ヒアルロン酸産生促進用組成物 |
-
2022
- 2022-03-22 TW TW111110590A patent/TW202313077A/zh unknown
- 2022-03-22 EP EP22804365.9A patent/EP4342535A1/en active Pending
- 2022-03-22 JP JP2023522277A patent/JPWO2022244447A1/ja active Pending
- 2022-03-22 WO PCT/JP2022/013051 patent/WO2022244447A1/ja active Application Filing
- 2022-03-22 CN CN202280032086.9A patent/CN117279521A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11228425A (ja) * | 1998-02-13 | 1999-08-24 | Takeda Food Products Ltd | Il−12産生誘導組成物 |
JP2010006801A (ja) | 2008-05-30 | 2010-01-14 | Bio Medical Research Group:Kk | 乳酸菌配合物及びその製造方法 |
JP2010095465A (ja) * | 2008-10-16 | 2010-04-30 | House Wellness Foods Kk | 乳酸菌含有免疫賦活用組成物 |
JP2010235534A (ja) | 2009-03-31 | 2010-10-21 | Fancl Corp | 骨粗鬆症の予防又は治療用剤 |
JP2015096476A (ja) * | 2013-11-15 | 2015-05-21 | 株式会社東洋新薬 | コラーゲン産生促進用組成物、コラーゲン吸収促進用組成物、抗肥満用組成物 |
JP2017114814A (ja) * | 2015-12-24 | 2017-06-29 | 丸善製薬株式会社 | 化粧料 |
WO2019045037A1 (ja) * | 2017-09-01 | 2019-03-07 | ハウスウェルネスフーズ株式会社 | ヒアルロン酸産生促進用組成物 |
Non-Patent Citations (2)
Title |
---|
INT IMMUNOPHARMACOL., vol. 25, no. 2, 2015, pages 321 - 331 |
KIMOTO, HIROMI: "Potential probiotic lactic acid bacterium Lactococcus lactis H61 contributing to high quality of life", JAPANESE JOURNAL OF LACTID ACID BACTERIA, vol. 29, no. 2, 1 January 2018 (2018-01-01), pages 69 - 78, XP093006175, DOI: 10.4109/jslab.29.69 * |
Also Published As
Publication number | Publication date |
---|---|
TW202313077A (zh) | 2023-04-01 |
JPWO2022244447A1 (ja) | 2022-11-24 |
CN117279521A (zh) | 2023-12-22 |
EP4342535A1 (en) | 2024-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019243093B2 (en) | Nutritional composition, food/drink composition using nutritional composition, and modified milk powder using nutritional composition | |
KR101492650B1 (ko) | 혈중 아디포넥틴 농도 증가 촉진 및/또는 감소 억제제 및 내장 지방 축적 억제제 | |
US20210196767A1 (en) | Obesity treatment using probiotics, composition for reducing body fat, and composition for reducing waist circumference | |
WO2017130859A1 (ja) | 神経細胞死抑制剤 | |
AU2016370012B2 (en) | Agent for promoting growth of, and/or suppressing decrease in, Bifidobacterium bacteria and/or lactic acid bacteria | |
CN114786692A (zh) | 用于调节肠道免疫的新型益生菌组合物 | |
WO2018190407A1 (ja) | Toll様受容体2活性化用組成物 | |
JP5229977B2 (ja) | 血中アディポネクチン濃度増加促進及び/又は減少抑制剤 | |
WO2015046407A1 (ja) | 免疫疾患予防剤 | |
JP2019077694A (ja) | 免疫疾患予防剤 | |
TW201701891A (zh) | 大腸炎抑制劑 | |
JP5209294B2 (ja) | インターロイキン12産生促進剤 | |
CN111065274A (zh) | 用于促进血液中的氨基酸浓度提高的发酵乳 | |
WO2020067422A1 (ja) | T細胞を活性化するための組成物 | |
JP2021112165A (ja) | 組成物並びに飲食品組成物、栄養組成物および調製乳 | |
WO2022244447A1 (ja) | 破骨前駆細胞の破骨細胞への分化抑制用組成物及び骨代謝改善用組成物 | |
JP6767157B2 (ja) | インターフェロンλ誘導剤 | |
US11045508B2 (en) | Composition for preventing or improving impaired renal function, pharmaceutical composition, food/beverage composition, and method of preventing or improving impaired renal function using the composition for preventing or improving impaired renal function | |
JP2017031109A (ja) | 形質細胞様樹状細胞誘導剤 | |
WO2022168341A1 (ja) | 免疫賦活作用を有する組成物 | |
JP7333732B2 (ja) | 筋肉量及び/又は筋力の維持、或いは筋肉量及び/又は筋力の低下抑制用組成物、並びに、該組成物を用いた医薬品組成物及び飲食品組成物 | |
JP7309436B2 (ja) | 腎機能障害予防又は改善用組成物、並びに、該腎機能障害予防又は改善用組成物を用いた医薬品組成物及び飲食品組成物 | |
JP7326075B2 (ja) | 腎機能障害の予防又は改善用組成物、並びに、該組成物を用いた医薬品組成物及び飲食品組成物 | |
JP7299744B2 (ja) | 血中尿酸値低減用組成物、及び高尿酸血症予防又は改善用組成物、並びに、該組成物を用いた医薬品組成物及び飲食品組成物 | |
JP7331310B2 (ja) | 免疫賦活活性を有する乳酸菌又はその処理物の保存時間経過による免疫賦活活性の低下を抑制するための組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22804365 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023522277 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2301007423 Country of ref document: TH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022804365 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022804365 Country of ref document: EP Effective date: 20231218 |